MedTrace Logo

Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer

NCT00701168 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2017-08-23

No results posted yet for this study

Summary

The purpose of this protocol is to provide supervised and limited access to Therasphere® treatment for patients with primary liver cancer and chemotherapy refractory liver metastasis who cannot be treated by surgical removal of the affected part of the liver. Patient response to treatment and any side effects of Therasphere® treatment will be examined.

Conditions

  • Carcinoma, Hepatocellular
  • Neoplasm Metastasis

Interventions

DEVICE

yttrium Y 90 microspheres (Therasphere®)

This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.

Sponsors & Collaborators

  • Leo W. Jenkins Cancer Center

    lead OTHER

Principal Investigators

  • Suzanne Russo, MD · East Carolina University School of Medicine

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00701168 on ClinicalTrials.gov